

PRACTICE GUIDELINES

2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: Executive Summary

A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance

Writing Committee Members

Philip Greenland, MD, FACC, FAHA, *Chair*

Joseph S. Alpert, MD, FACC, FAHA
George A. Beller, MD, MACC, FAHA
Emelia J. Benjamin, MD, ScM, FACC, FAHA*†
Matthew J. Budoff, MD, FACC, FAHA‡§||
Zahi A. Fayad, PhD, FACC, FAHA¶
Elyse Foster, MD, FACC, FAHA#
Mark A. Hlatky, MD, FACC, FAHA\$**
John McB. Hodgson, MD, FACC, FAHA,
FSCAI‡§**††
Frederick G. Kushner, MD, FACC, FAHA†‡‡
Michael S. Lauer, MD, FACC, FAHA

Leslee J. Shaw, PhD, FACC, FAHA§§
Sidney C. Smith, Jr, MD, FACC, FAHA||¶¶
Allen J. Taylor, MD, FACC, FAHA##
William S. Weintraub, MD, FACC, FAHA
Nanette K. Wenger, MD, MACC, FAHA

*ACCF/AHA Task Force on Performance Measures Liaison; †Recused from voting on Section 10, Lipoprotein-Associated Phospholipase A2; ‡Recused from voting on Section 21, Coronary Computed Tomography Angiography; §Recused from voting on Section 23, Diabetes Mellitus; ||SAIP Representative; ¶SCMR Representative; #ASE Representative; **Recused from voting on Section 20, Calcium Scoring Methods; ††SCAI Representative; ‡‡Recused from voting on Section 5, Lipoprotein and Apolipoprotein Assessments; §§ASNC Representative; |||ACCF/AHA Task Force on Practice Guidelines Liaison; ¶¶Recused from voting on Section 7, Measurement of C-Reactive Protein; ##SCCT Representative.

ACCF/AHA Task Force Members

Alice K. Jacobs, MD, FACC, FAHA, *Chair, 2009–2011*
Sidney C. Smith, Jr, MD, FACC, FAHA,
Immediate Past Chair, 2006–2008†††
Jeffrey L. Anderson, MD, FACC, FAHA,
Chair-Elect

Nancy Albert, PhD, CCNS, CCRN
Christopher E. Buller, MD, FACC†††
Mark A. Creager, MD, FACC, FAHA
Steven M. Ettinger, MD, FACC
Robert A. Guyton, MD, FACC

Jonathan L. Halperin, MD, FACC, FAHA
Judith S. Hochman, MD, FACC, FAHA
Frederick G. Kushner, MD, FACC, FAHA
Rick Nishimura, MD, FACC, FAHA†††
E. Magnus Ohman, MD, FACC
Richard L. Page, MD, FACC, FAHA†††
William G. Stevenson, MD, FACC, FAHA
Lynn G. Tarkington, RN†††
Clyde W. Yancy, MD, FACC, FAHA

†††Former ACCF/AHA Task Force member during this writing effort.

This document was approved by the American College of Cardiology Foundation Board of Trustees, the American Heart Association Science Advisory and Coordinating Committee, and all cosponsoring organizations in September 2010.

The American College of Cardiology Foundation requests that this document be cited as follows: Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, Hlatky MA, Hodgson JMcB, Kushner FG, Lauer MS, Shaw LJ, Smith SC, Jr., Taylor AJ, Weintraub WS, Wenger NK. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol* 2010;56:2182–99.

This article is copublished in *Circulation* and the *Journal of Cardiovascular Computed Tomography*.

Copies: This document is available on the World Wide Web sites of the American College of Cardiology Foundation (www.cardiosource.org) and the American Heart Association (my.americanheart.org). For copies of this document, please contact the Elsevier Inc. Reprint Department, fax (212) 633-3820, e-mail reprints@elsevier.com.

Permissions: Modification, alteration, enhancement, and/or distribution of this document are not permitted without the express permission of the American College of Cardiology Foundation. Please contact Elsevier's permission department at healthpermissions@elsevier.com.

TABLE OF CONTENTS

Preamble	2183
1. Introduction	2186
1.1. Methodology and Evidence Review	2186
1.2. Organization of the Writing Committee	2186
1.3. Document Review and Approval	2186
1.4. Magnitude of the Problem of Cardiovascular Risk in Asymptomatic Adults	2187
1.5. Assessing the Prognostic Value of Risk Factors and Risk Markers	2187
1.6. Usefulness in Motivating Patients or Guiding Therapy	2188
1.7. Economic Evaluation of Novel Risk Markers	2188
2. Recommendation for Global Risk Scoring	2188
3. Recommendation for Family History	2188
4. Recommendation for Genomic Testing	2188
5. Recommendation for Lipoprotein and Apolipoprotein Assessments	2188
6. Recommendation for Measurement of Natriuretic Peptides	2189
7. Recommendations for Measurement of C-Reactive Protein	2189
8. Recommendation for Measurement of Hemoglobin A1C	2189
9. Recommendations for Testing for Microalbuminuria	2189
10. Recommendation for Lipoprotein-Associated Phospholipase A2	2189
11. Recommendations for Resting Electrocardiogram	2189
12. Recommendations for Transthoracic Echocardiography	2189
13. Recommendation for Measurement of Carotid Intima-Media Thickness	2189
14. Recommendation for Brachial/Peripheral Flow-Mediated Dilation	2189

15. Recommendation for Specific Measures of Arterial Stiffness	2190
16. Recommendation for Measurement of Ankle-Brachial Index	2190
17. Recommendation for Exercise Electrocardiography	2190
18. Recommendation for Stress Echocardiography	2190
19. Recommendations for Myocardial Perfusion Imaging	2190
20. Recommendations for Calcium Scoring Methods	2190
21. Recommendation for Coronary Computed Tomography Angiography	2190
22. Recommendation for Magnetic Resonance Imaging of Plaque	2190
23. Recommendations for Patients With Diabetes Mellitus	2190
24. Recommendations for Special Considerations in Women	2190
25. Clinical Implications of Risk Assessment: Concluding Comments	2191
Appendix 1. Author Relationships With Industry and Other Entities	2191
Appendix 2. Reviewer Relationships With Industry and Other Entities	2193
References	2197

Preamble

It is essential that the medical profession play a central role in critically evaluating the evidence related to drugs, devices, and procedures for the detection, management, or prevention of disease. Properly applied, rigorous, expert analysis of the available data documenting absolute and relative benefits and risks of these therapies and procedures can improve the effectiveness of care, optimize patient outcomes, and favorably affect the cost of care by focusing resources on the most effective strategies. One important use of such data is the production of clinical practice guidelines that, in turn, can provide a foundation for a variety of other applications,

Download English Version:

<https://daneshyari.com/en/article/2948160>

Download Persian Version:

<https://daneshyari.com/article/2948160>

[Daneshyari.com](https://daneshyari.com)